MedTrace Logo

Naturalistic Study of Microdosing With Psilocybin

NCT05160220 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-12-16

No results posted yet for this study

Summary

This study seeks to understand the neural, cognitive and behavioral effects of low doses of psilocybin administered in the form of dried mushroom material (0.5 g of Psilocybe cubensis) consumed in natural settings following a placebo-controlled double-blind experimental design.

Conditions

  • Cognitive Change
  • Creativity
  • Mood Change
  • Sleep

Interventions

DRUG

Psilocybin

0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.

DRUG

Placebo

0.5 g dried edible non-psychoactive mushroom material.

Sponsors & Collaborators

  • National Council of Scientific and Technical Research, Argentina

    lead OTHER_GOV

Principal Investigators

  • Enzo Tagliazucchi, PhD · National Council of Scientific and Technical Research, Argentina

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2021-06-30
Completion
2021-10-01

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05160220 on ClinicalTrials.gov